7BIO (7-Bromoindirubin-3-Oxime) 是靛玉红的衍生物。7BIO (7-Bromoindirubin-3-Oxime) 对细胞周期蛋白依赖性激酶5 (CDK5) 和糖原合酶激酶-3β (GSK3β) 具有抑制作用。7BIO (7-Bromoindirubin-3-Oxime) 抑制 Aβ 寡聚体诱导的神经炎症、突触损伤、tau 过度磷酸化、星形胶质细胞和小胶质细胞的活化,并减轻 Aβ 寡聚体诱导的小鼠认知障碍[1]。
生物活性 | 7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice[1]. |
IC50& Target | |
体外研究 (In Vitro) | 7BIO (1 and 10 μM; 24 hours) has neuroprotective effects and can prevent, but cannot rescue Aβ1–42 oligomer-induced cell death in SH-SY5Y cells[1].
Cell Viability Assay[1] Cell Line: | SH-SY5Y cells | Concentration: | 1 and 10 μM | Incubation Time: | 24 hours | Result: | Inhibit Aβ oligomer-induced neuronal death. 7BIO prevented, but did not rescue Aβ1–42 oligomer-induced cell death in SH-SY5Y cells. |
|
体内研究 (In Vivo) | 7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) significantly attenuates Aβ oligomer-induced impairment of recognition, spatial learning and memory in mice[1]. 7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) decreases Aβ oligomer-induced increase of TNF-α and IL-6 production in the brain and the expression of synapsin-1 and PSD-95 in the hippocampal region of mice[1]. 7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) attenuates Aβ oligomer-induced increase expression of pTau, activation of microglia and astrogliosis in the brain of mice[1]. 7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) prevents decreased expression of pSer9-GSK3β and has no significant effects on the Tau protein level[1].
Animal Model: | 8 weeks mice (30 g)[1] | Dosage: | 2.3, 7.0, and 23.3 μg/kg | Administration: | bilateral ventricle injection | Result: | Attenuates Aβ oligomer-induced impairment of recognition, spatial learning and memory in mice. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : 250 mg/mL(701.91 mM;Need ultrasonic) Ethanol : 50 mg/mL(140.38 mM;Need ultrasonic) 配制储备液 1 mM | 2.8076 mL | 14.0382 mL | 28.0765 mL | 5 mM | 0.5615 mL | 2.8076 mL | 5.6153 mL | 10 mM | 0.2808 mL | 1.4038 mL | 2.8076 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% EtOH 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (7.02 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.02 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.84 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 *以上所有助溶剂都可在本网站选购。
|